AI-generated · cited to primary sources · not investment advice
Sai Life (544306) Feb 2026 Filing Analysis
Does management do what it says?
The company achieved an EBITDA margin of 34% in Q3 FY26 and 30% for 9M FY26, reaching the upper end of their long-term goal ahead of schedule. (4 exceeded, 1 met across 5 tracked commitments)
“Invested ₹405 Cr as on date in capital expenditure, against a plan of ₹700 Cr for FY26”
Targeting completion of the new CMC Process R&D Center by September 2026. — target: Completion (+1 more commitment)
“Sai Life Sciences has commenced construction of a new CMC Process R&D Center at its Hyderabad campus, targeted for completion by September 2026. The facility will double Process R&D capacity.”
Peptide process development and pilot facility targeted for commissioning in September '26. — target: Commissioning of peptide pilot scale facility (+4 more commitments)
“Our peptide process development and pilot facility is also targeted for September '26 to significantly expand both our discovery and development peptide capabilities up to pilot scale.”
See the full cited Management analysis of Sai Life
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.